Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Hashem, Anwar M ^a,c   Flaman, Anathea S ^a   Farnsworth, Aaron ^a   Brown, Earl G ^c   van Domselaar, Gary ^b   He, Runtao ^b   Li, Xuguang ^a,c  

^a HEALTH CANADA   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AURINTRICARBOXYLIC ACID; HISTIDINE; ION CHANNEL; NUCLEIC ACID; OSELTAMIVIR; TYROSINE; VIRUS SIALIDASE; ENZYME INHIBITOR; SIALIDASE; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS B; KIDNEY CELL; NONHUMAN; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; ANTIVIRAL RESISTANCE; CELL LINE; CELL PROTECTION; CULTURE MEDIUM; DOG; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; PHYSIOLOGY; ULTRASTRUCTURE; VIRUS INACTIVATION; VIRUS INCLUSION;

CERCOPITHECINE HERPESVIRUS 1; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

AMANTADINE; ANIMALS; AURINTRICARBOXYLIC ACID; CELL LINE; CULTURE MEDIA; CYTOPROTECTION; DOGS; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; ENZYME INHIBITORS; INCLUSION BODIES, VIRAL; INFLUENZA A VIRUS; INFLUENZAVIRUS B; NEURAMINIDASE; OSELTAMIVIR; RNA, VIRAL; VIRUS INACTIVATION; VIRUS REPLICATION;

EID: 77949497846     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008350     Document Type: Article

References (50)

1. Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: 6852-6862.
2. Hannoun C, Megas F, Piercy J (2004) Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103: 133-138.
3. Puthavathana P, Auewarakul P, Charoenying PC, Sangsiriwut K, Pooruk P, et al. (2005) Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J Gen Virol 86: 423-433.
4. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009) Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med 360: 2605-2615.
5. Ludwig S, Planz O, Pleschka S, Wolff T (2003) Influenza-virus-induced signaling cascades: targets for antiviral therapy? Trends Mol Med 9: 46-52.
6. Gerhard W, Mozdzanowska K, Zharikova D (2006) Prospects for universal influenza virus vaccine. Emerg Infect Dis 12: 569-574.
7. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, et al. (2006) Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24: 4475-4481.
8. Fedson DS (2003) Pandemic influenza and the global vaccine supply. Clin Infect Dis 36: 1552-1561.
9. Centers for Disease Control and Prevention (CDC) (2004) Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine-Colorado, December 2003. MMWR Morb Mortal Wkly Rep 53: 8-11.
10. Banzhoff A, Pellegrini M, Del GG, Fragapane E, Groth N, et al. (2008) MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses 2: 243-249.
11. Nordin J, Mullooly J, Poblete S, Strikas R, Petrucci R, et al. (2001) Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 184: 665-670.
12. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, et al. (2007) Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 25: 2842-2851.
13. Chun S, Li C, Van DG, Wang J, Farnsworth A, et al. (2008) Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 26: 6068-6076.
14. Palese P (2004) Influenza: old and new threats. Nat Med 10: S82-S87.
15. Brown EG (2000) Influenza virus genetics. Biomed Pharmacother 54: 196-209.
16. de J, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
17. Hunt DM, Wagner RR (1975) Inhibition by aurintricarboxylic acid and polyethylene sulfonate of RNA transcription of vesicular stomatitis virus. J Virol 16: 1146-1153.
18. Walther W, Stein U, Siegel R, Fichtner I, Schlag PM (2005) Use of the nuclease inhibitor aurintricarboxylic acid (ATA) for improved non-viral intratumoral in vivo gene transfer by jet-injection. J Gene Med 7: 477-485.
19. Cushman M, Wang PL, Chang SH, Wild C, De CE, et al. (1991) Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. J Med Chem 34: 329-337.
20. Balzarini J, Mitsuya H, De CE, Broder S (1986) Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem Biophys Res Commun 136: 64-71.
21. He R, Adonov A, Traykova-Adonova M, Cao J, Cutts T, et al. (2004) Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. Biochem Biophys Res Commun 320: 1199-1203.
22. Myskiw C, Deschambault Y, Jefferies K, He R, Cao J (2007) Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors. J Virol 81: 3027-3032.
23. Sidwell RW, Bailey KW, Wong MH, Huffman JH (1995) In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. Chemotherapy 41: 455-461.
24. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF (2005) In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res 68: 10-17.
25. Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW (2001) Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45: 743-748.
26. Govorkova EA, Fang HB, Tan M, Webster RG (2004) Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48: 4855-4863.
27. Aymard M, Ferraris O, Gerentes L, Jolly J, Kessler N (2003) Neuraminidase assays. Dev Biol (Basel) 115: 75-83.
28. Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, et al. (2000) Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 280: 291-300.
29. Liu C, Eichelberger MC, Compans RW, Air GM (1995) Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 69: 1099-1106.
30. Palese P, Compans RW (1976) Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 33: 159-163.
31. Air GM, Laver WG (1989) The neuraminidase of influenza virus. Proteins 6: 341-356.
32. Ohuchi M, Asaoka N, Sakai T, Ohuchi R (2006) Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 8: 1287-1293.
33. Abed Y, Baz M, Boivin G (2006) Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral Ther 11: 971-976.
34. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, et al. (2008) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 57: 1-60.
35. Belshe RB (2009) Implications of the Emergence of a Novel H1 Influenza Virus. N Engl J Med 360: 2667-2668.
36. Regoes RR, Bonhoeffer S (2006) Emergence of drug-resistant influenza virus: population dynamical considerations. Science 312: 389-391.
37. Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, Grog I, et al. (2008) Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 41: 25-28.
38. Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55 Suppl 1: i5-i21.
39. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, et al. (2001) Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20: 127-133.
40. Tsi CJ, Chao Y, Chen CW, Lin WW (2002) Aurintricarboxylic acid protects against cell death caused by lipopolysaccharide in macrophages by decreasing inducible nitric-oxide synthase induction via IkappaB kinase, extracellular signal-regulated kinase, and p38 mitogen-activated protein kinase inhibition. Mol Pharmacol 62: 90-101.
41. Chen CW, Chao Y, Chang YH, Hsu MJ, Lin WW (2002) Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid. Br J Pharmacol 137: 1011-1020.
42. Haimsohn M, Beery R, Karasik A, Kanety H, Geier A (2002) Aurintricarboxylic acid induces a distinct activation of the IGF-I receptor signaling within MDA-231 cells. Endocrinology 143: 837-845.
43. Beery R, Haimsohn M, Wertheim N, Hemi R, Nir U, et al. (2001) Activation of the insulin-like growth factor 1 signaling pathway by the antiapoptotic agents aurintricarboxylic acid and evans blue. Endocrinology 142: 3098-3107.
44. Steward DL, Martin J, Grollman AP (1977) Inhibition of influenza virus by triphenylmethane compounds. Ann N Y Acad Sci 284: 638-649.
45. Hung HC, Tseng CP, Yang JM, Ju YW, Tseng SN, et al. (2009) Aurintricarboxylic acid inhibits influenza virus neuraminidase. Antiviral Res 81: 123-131.
46. Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, et al. (2009) Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res 81: 16-24.
47. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA (2007) Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 12: 363-370.
48. Matsuno H, Kozawa O, Niwa M, Tanabe K, Ichimaru K, et al. (1998) Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb Haemost 79: 865-71.
49. Glasspool-Malone J, Malone RW (1999) Marked enhancement of direct respiratory tissue transfection by aurintricarboxylic acid. Human Gene Therapy 10: 1703-1713.
50. Glasspool-Malone J, Malone RW (2002) Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields. Methods in Enzymology 346: 72-91.